Table 1 Baseline characteristics of the participants according to incident CKD status

n, %

1905 (90.6)

198 (9.4)

–

Age (years)

58.9 ± 8.9

63.1 ± 10.1

<0.0001

Male (n, %)

753 (39.5)

73 (36.9)

0.47

BMI (kg/m²)

24.7 ± 3.4

25.5 ± 3.8

0.0006

Waist circumference (cm)

86.3 ± 9.4

89.5 ± 9.7

<0.0001

Current drinker (n, %)

344 (18.1)

40 (20.2)

0.58

Current smoker (n, %)

382 (20.1)

39 (19.7)

0.81

SBP (mmHg)

134 ± 24

144 ± 27

<0.0001

DBP (mmHg)

78 ± 10

81 ± 10

0.001

Triglyceride (mmol/l)

1.40 (0.96–2.02)

1.48 (1.01–2.41)

0.02

LDL-C (mmol/l)

2.40 ± 0.68

2.35 ± 0.68

0.30

HDL-C (mmol/l)

1.37 ± 0.30

1.34 ± 0.31

0.31

Total cholesterol (mmol/l)

5.15 ± 0.96

5.11 ± 1.05

0.64

FPG (mmol/l)

5.1 (4.7–5.8)

5.6 (5.0–7.0)

<0.0001

HbA1c (%)

6.1 (5.7–6.5)

6.4 (5.9–7.6)

<0.0001

TSH (μIU/ml)

1.44 (1.03–2.14)

1.44 (1.01–2.07)

0.35

FT3 (pmol/l)

4.65 ± 0.55

4.72 ± 1.11

0.16

FT4 (pmol/l)

14.27 ± 1.80

14.85 ± 2.36

<0.0001

TPOAb (IU/ml)

0.30 (0.17–0.73)

0.32 (0.18–0.71)

0.55

TGAb (IU/ml)

1.06 (0.71–2.44)

0.93 (0.71–1.91)

0.09

eGFR (ml/min/1.73 m²)

92.4 ± 12.2

88.9 ± 14.4

0.0001

Urinary ACR (mg/g)

4.67 (2.39–8.71)

9.57 (4.41–16.87)

<0.0001

Use of antidiabetic drugs (n, %)

208 (10.9)

52 (26.3)

<0.0001

Use of antihypertensive drugs (n, %)

426 (22.4)

63 (31.8)

0.003